STOCK TITAN
  1. Home
  2. News
  3. BNGO

Bionano Genomics Inc - BNGO STOCK NEWS

Welcome to our dedicated news page for Bionano Genomics (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bionano Genomics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bionano Genomics's position in the market.

News
Bionano Announces Third OEM Partner has Received China NMPA Approval for DNA Isolation Products for IVD Use of OGM
Rhea-AI Summary
Bionano's OEM partner Ecobono obtains NMPA approval for DNA isolation kits, allowing sales to independent clinical laboratories and Chinese hospitals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
none
-
News
Largest Study of Mendelian Disease Highlights how OGM, alongside other Techniques, May Enhance Success Rates in Identifying Molecular Causes of Genetic Disease
Rhea-AI Summary
Bionano Genomics publishes study on challenges in detecting causal variants in Mendelian disease, highlighting the potential of multiple techniques and optical genome mapping (OGM)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
none
-
News
Bionano Announces Peer-Reviewed Publication on the Utility of Combining OGM and WES for Evaluation of Pediatric Leukemia
Rhea-AI Summary
Bionano Genomics announces publication on the utility of optical genome mapping and whole-exome sequencing in understanding pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.08%
Tags
none
News
Bionano Announces Publication Demonstrating Utility of OGM as an Alternative to KT and CMA for Evaluating CRISPR-Edited Cells as Part of Stem Cell Therapy Development
Rhea-AI Summary
Bionano Genomics demonstrates the utility of optical genome mapping (OGM) in evaluating CRISPR-Cas9 edited genomes for stem cell therapy. Approximately 15% of edited genomes had potentially pathogenic deletions. Comprehensive analysis of edited genomes is important for developing therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.59%
Tags
none
-
News
Bionano Announces Second OEM Partner has Received China NMPA Approval for DNA Extraction and Labeling Products for IVD Use of OGM in Reproductive Health
Rhea-AI Summary
Bionano's OEM partner A-smart MedTech obtains NMPA approval for DNA isolation and labeling kits for OGM in China
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.27%
Tags
none
-
News
Bionano Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
Rhea-AI Summary
Bionano Genomics regains compliance with Nasdaq's minimum bid price requirement, closing bid price at $1.00 per share or greater for 10 consecutive business days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.66%
Tags
none
News
Bionano Laboratories Receives College of American Pathologists (CAP) Accreditation for its Clinical Laboratory
Rhea-AI Summary
Bionano Laboratories, a laboratory services business of Bionano Genomics, Inc., has received Laboratory Accreditation from the College of American Pathologists (CAP) for its Clinical Laboratory Improvement Amendments (CLIA)-certified reference lab. CAP accreditation is awarded to laboratories that meet stringent requirements and maintain the highest standards for laboratory operations. This accreditation is important for reimbursement from insurance companies and for conducting projects under a more robust regulatory structure. The achievement is expected to support the proliferation of optical genome mapping (OGM) in various markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.19%
Tags
none
-
News
Bionano Announces CFO Transition and Appointment of Gülsen Kama as Chief Financial Officer
Rhea-AI Summary
Bionano Genomics announces Gülsen Kama as new CFO, effective September 11, 2023. Kama has a strong background in financial strategy and experience in managing expenses for profitable growth. She previously served as CFO at Northern Data AG and held leadership roles at Quest Diagnostics, FedEx, United Airlines, A&P, and AIG. The senior leadership team is excited to partner with Kama to propel the company to new heights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.28%
Tags
management
-
News
Bionano Announces Presentation of Optical Genome Mapping (OGM) Utility Across Cancer Research Applications at the Cancer Genomics Consortium (CGC) 2023 Annual Meeting
Rhea-AI Summary
Bionano Genomics to showcase its optical genome mapping (OGM) technology at the Cancer Genomics Consortium (CGC) 2023 Annual Meeting. The company will present scientific platform and poster presentations, introduce new products, and host a panel discussion with cancer genomics experts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
none
News
Bionano Reports Second Quarter 2023 Results and Highlights Recent Business Progress
Rhea-AI Summary
Bionano Genomics, Inc. reported Q2 2023 financial results with revenue of $8.7 million, a 30% increase YoY. The installed base of Saphyr® systems reached 281, a 43% increase YoY. They sold 7,062 nanochannel array flowcells, a 108% increase YoY. The company also announced new products and software releases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.37%
Tags
earnings
Stock BNGO logo
Bionano Genomics Inc

Nasdaq:BNGO

BNGO Rankings

#4704 Ranked by Market Cap
#5501 Ranked by Stock Gains
N/A Ranked by Dividends

BNGO Stock Data

52.38M
54.49M
0.5%
11.91%
9.64%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
US
San Diego

About BNGO

at bionano genomics®, we are committed to unlocking understanding of genome biology to advance the promise of genomics in areas including cancer and human disease, agricultural bioengineering and genome discovery. our team is not afraid to venture into uncharted territory to look for answers. we welcome the curious and provide a place where those who are not satisfied with the status quo can feel at home. our next-generation genome mapping and analysis tools help researchers see true genome structure to fill in what’s missing from sequencing-based data. saphyr™, our high-speed, high-throughput whole genome mapping solution, offers unmatched structural variation discovery capabilities and the ability to construct the most complete genome assemblies. at bionano, we are invested in the success of our customers and users around the world, and are dedicated to supporting them with the tools, resources and support they need to achieve their goals and make a real impact on improving quality o